why Teva Pharmaceutical Industries Limited [TEVA] is a Good Choice for Investors After New Price Target of $11.92
Edison Baldwin May 5, 2021 Teva Pharmaceutical Industries Limited [NYSE: TEVA] loss -1.06% or -0.11 points to close at $10.25 with a heavy trading volume of 7004076 shares. The company report on June 28, 2021 that Teva and Bioeq Announce Commercial Partnership for Biosimilar. Agreement includes commercializing biosimilar candidate of ophthalmology drug ranibizumab (Lucentis®) in Europe, Canada, Israel and global markets. Teva Pharmaceutical Industries Ltd. (NYSE: and TASE: TEVA) and Bioeq AG (“Bioeq”) announced that they have entered into a strategic partnership for the exclus...